Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis

Managed Care Interface

Volumn 19, Issue 6, 2006, Pages 39-43

  Simpson, Jason F ^a   Yelverton, Christopher B ^a   Balkrishnan, Rajesh ^b   Fleischer Jr , Alan ^a   Lide, William ^c   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; EFALIZUMAB; ETANERCEPT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MANAGED CARE; PHOTOTHERAPY; PRESCRIPTION; PSORIASIS; REIMBURSEMENT; SKIN DISEASE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

COST SHARING; HUMANS; INSURANCE, HEALTH; PHOTOTHERAPY; PSORIASIS;

EID: 33746648112     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fisher VS: Clinical monograph for drug formulary review: Systemic agents for psoriasis/psoriatic arthritis. J Manag Care Pharm 2005;11:33-55.
2. Feldman SR, Garton R, Averett W, et al: Strategy to manage the treatment of severe psoriasis: Considerations of efficacy, safety, and cost. Expert Opin Pharmacother 2003;4:1525-1533.
3. Feldman SR, Pearce DJ: Management and cost of severe psoriasis: The role of new biologics. Expert Rev Pharmacoeconomics Outcomes Res 2004;4:573-579.
4. Stern RS, Laird N: The carcinogenic risk of treatments for severe psoriasis: Photochemotherapy Follow-Up Study. Cancer 1994;73:2759-2764.
5. Griffiths CE, Clark CM, Chalmers RJ, et al: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;40:1-125.
6. Weischer M, Blum A, Eberhard F, et al: No evidence for increased skin cancer risk in psoriasis patients treated with broad-band or narrowband UVB phototherapy: A first retrospective study. Acta Derm Venereol 2004;84:370-374.
7. Man I, Crombie IK, Dawe RS, et al: The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: Early follow-up data. Br J Dermatol 2005;152:755-757.
8. Spuls PI, Witkamp L, Bossuyt PM, et al: A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997;137:943-949.
9. Green C, Lakshmipathi T, Johnson BE, et al: A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 1992;127:5-9.
10. Statistics. National Psoriasis Foundation (www.psoriasis. org/about/stats), 2006.
11. Housman TS, Rohrback JM, Fleischer AB, et al: Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol 2002;46:557-559.
12. Drug Topics Red Book. Montvale, NJ, Medical Economics, 2005.
13. Kulkarni AS, Balkrishnan R, Richmond DW, et al: Medication related factors affecting health care outcomes and costs in patients with psoriasis in the United States. J Am Acad Dermatol 2005;52:27-31.
14. Singri P, West DP, Gordon KB: Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol 2002;138:657-663.